T-Cell Engaging Bispecific Antibodies: Preparing Oncology Pharmacists to Optimize Patient Care

This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2022.

Program Description

Bispecific antibodies (BsAbs) offer patients with hematologic and solid tumors the benefit of reactivating T cells to trigger an immune response and potentially induce remission. Use of T-cell−engaging BsAbs in treatment of cancer can minimize potential for adverse effects compared with other immunotherapies. With one BsAb currently approved for treatment of acute lymphocytic leukemia and more in the pipeline for multiple cancers, pharmacists should be knowledgeable about the potential impact of these agents in the oncology landscape. This program will introduce pharmacists to data currently available for the approved BsAb and detail mechanism of action and considerations for treatment selection and sequencing of emerging BsAbs. Clinical data including efficacy and safety considerations based on therapy indication will be examined. Practical strategies to overcome complexities of care and challenges with administration of and access to BsAb therapy as these agents enter the treatment paradigm of patients with cancer will also be discussed.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 29, 2022
Expiration date: April 29, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the advantages of T-cell−engaging bispecific antibodies (BsAbs) in the treatment of cancer
• Examine the efficacy data supporting the use of T-cell−engaging BsAbs in the treatment of cancer
• Employ strategies to overcome operational challenges associated with the use of T-cell−engaging BsAbs in cancer care

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-194-H01-P. The activity is available for CE credit through April 29, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, watch the symposium in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Sarah E. Stump, PharmD, BCPS, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms